文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

放射线可视黏性水凝胶间隔物在前列腺癌放疗中的应用:一项前瞻性2期研究

Application of a Radiopaque Viscous Hydrogel Spacer for Prostate Cancer Radiation Therapy: A Prospective Phase 2 Study.
PubMed 文献 · Pract Radiat Oncol · 2023-10-03

该前瞻性2期研究在30例前列腺癌患者前列腺与直肠壁之间注射中位10 mL放射线可视黏性水凝胶间隔物(RVS),并与30例初始液体间隔物对照比较。未观察到操作或器械相关不良事件,未见水凝胶迁移,放疗后3个月体积缩小25%,12个月时3例(10%)检出小残留;RVS组前列腺与直肠间距更大,用户评估更易控制注射且锥形束CT可见性好。

要点

  • RVS注射未观察到操作或器械相关不良事件,未见水凝胶迁移。
  • 放疗后3个月体积缩小25%,12个月时3例(10%)检出小残留。
  • RVS组前列腺与直肠间距大于初始液体间隔物组,凝胶对称性相当。

核心结论

  • 注射放射线可视黏性水凝胶间隔物在多数病例中使前列腺与直肠间距大于10 mm。
  • 高剂量区内直肠体积和放疗毒性均很低。
  • 与常规水凝胶间隔物相比,优势主要为注射过程中放置控制改善和CT可见性好。

研究设计与样本

  • 前瞻性2期研究,30例患者在前列腺与直肠壁之间注射中位10 mL放射线可视黏性水凝胶间隔物。
  • 放疗期间行锥形束CT,放疗后3个月和12个月行磁共振成像。
  • 结果与30例初始液体间隔物对照组患者比较。

主要发现

  • 未观察到操作或器械相关不良事件,任何病例均未发现水凝胶迁移迹象。
  • 放疗后3个月体积缩小25%,放疗后12个月3例(10%)检出小残留。
  • 90%等剂量线内直肠体积百分比中位数为3.0%(四分位距1.5%-4.5%)。
  • 急性和晚期胃肠道毒性分别为17%和3%,均为1级。
  • 前列腺与直肠间距在基底部/中部/尖部的中位数RVS组大于初始液体间隔物组(分别为14/12/11 mm vs 12/10/10 mm),凝胶对称性(中线右侧 vs 左侧)相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to evaluate the application of a radiopaque viscous spacer (RVS) for prostate cancer radiation therapy (RT), including injection procedure, toxicity, treatment planning, image guidance, and imaging results up to 12 months after RT. METHODS AND MATERIALS: RVS (median, 10 mL) was injected between prostate and rectal wall in 30 patients. Cone beam computed tomography (CT) was performed during the course of RT, a magnetic resonance imaging 3 and 12 months after RT. Injection and treatment tolerability were analyzed. The resulting distribution was compared with a control group of 30 patients with an initially fluid spacer. RESULTS: Procedure- or device-related adverse events were not observed. Signs of hydrogel migration were not found in any case. The volume decreased by 25% at 3 months after RT, and small residues were detected at 12 months after RT in 3 cases (10%). The median rectal volume percentage within the 90% isodose was 3.0% (interquartile range, 1.5%-4.5%). Acute and late gastrointestinal toxicities were found in 17% and 3%, respectively (all grade 1). The median distance between prostate and rectum at the base/midplane/apex was greater for RVS in comparison to initially fluid spacer (14/12/11 mm vs 12/10/10 mm, respectively), the gel symmetry (right vs left from midline) was comparable. The application was assessed to be easier to control by the users, and visibility in cone beam CT as good. CONCLUSIONS: The injection of a radiopaque viscous hydrogel spacer resulted in a prostate-rectum distance of >10 mm in most cases. The resulting rectum volume within the high-dose region and RT toxicity were very low. Advantages in comparison to the conventional hydrogel spacer are predominantly an improved placement control during the injection process and good visibility on CT.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Pinkawa M, Haddad H, Schlenter M, et al. Application of a Radiopaque Viscous Hydrogel Spacer for Prostate Cancer Radiation Therapy: A Prospective Phase 2 Study. Pract Radiat Oncol. 2023. PMID: 37791943. doi:10.1016/j.prro.2023.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。